The DOI matches its Crossref record.
CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population
Abstract
Graves' disease (GD) is an autoimmune thyroid disease. Multiple genetic factors are believed to be involved in its pathogenesis, but the factors are largely unknown, except for sex (female disease preponderance) and the role of human leukocyte antigen (HLA) genes on chromosome 6. To understand the mechanisms underlying the development of GD, a search for non-HLA-linked genes is crucial, and we tested several candidate genes, including the CTLA-4 gene on chromosome 2q33. CTLA-4 molecules may either facilitate or down-regulate the second signal to T-cells, which is provided by the interaction between the two accessory molecules CD28 and B7. One hundred and thirty-three Caucasian patients (26 males) with GD and 85 local controls were included in this study. Polymerase chain reaction was used to amplify DNA containing the (AT)n repeat within the 3'-untranslated region of exon 3 of the CTLA-4 gene. The 5'-forward primer was radiolabeled, and amplified products were resolved on 5-7% sequencing gels. All subjects were previously typed for HLA class II alleles. Twenty-one alleles were observed with sizes ranging from 88-134 basepairs. In the association analysis, the genotype frequencies between GD patients and controls differed significantly (P = 0.012), and the difference was attributable to a higher frequency of the 106-basepair allele among patients (relative risk, 2.82). When the patients were subdivided with respect to sex and HLA, the phenotype frequencies of allele 106 was higher in the female patients with protective HLA specificities (DQA1*0201 positive/DQA1*0501 negative) than in those with susceptible HLA specificities (DQA1*0201 negative/DQA1*0501 positive; 81.8% vs. 45.5%; P = 0.026). The CTLA-4 gene or a closely associated gene (including CD28) confers susceptibility to GD. This association may be more important in female patients with protective HLA specificities, who otherwise would be at low risk of developing the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Weetman, A. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010263431707 · Cited by 834
Nistico, L. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.7.1075 · Cited by 809
The Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 634
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Kouki, T., Sawai, Y., Gardine, C. A., Fisfalen, M.-E., Alegre, M.-L., & DeGroot, L. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6606 · Cited by 505
Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy
Prabhakar, B. S., Bahn, R. S., & Smith, T. J. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0020 · Cited by 489
Tomer, Y., & Davies, T. F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0030 · Cited by 422
Marron, M. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.8.1275 · Cited by 407
CTLA4 Alanine-17 Confers Genetic Susceptibility to Graves’ Disease and to Type 1 Diabetes Mellitus1
Donner, H., Rau, H., Walfish, P. G., Braun, J., Siegmund, T., Finke, R., Herwig, J., Usadel, K. H., & Badenhoop, K. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3699 · Cited by 396
Polyglandular Autoimmune Syndromes: Immunogenetics and Long-Term Follow-Up
Dittmar, M., & Kahaly, G. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021845 · Cited by 367
CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms
Ligers, A., Teleshova, N., Masterman, T., Huang, W.-X., & Hillert, J. (2001) · Genes & Immunity · doi:10.1038/sj.gene.6363752 · Cited by 359
Immunogenetics of autoimmune thyroid diseases: a comprehensive review
Lee, H. J., Li, C. W., Hammerstad, S. S., Stefan, M., & Tomer, Y. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.07.009 · Cited by 351
“An A/G SNP at position 49 in exon 1 [77-82], an (AT)n microsatellite polymorphism in the 3′ untranslated region of exon 4 [83, 84], and the CT60 polymorphism in the 3′UTR have consistently been associated with AITD across different ethnicities.”
BackgroundThe etiology of autoimmune thyroid disease: A story of genes and environment
Tomer, Y., & Huber, A. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.02.007 · Cited by 351
Anjos, S., Nguyen, A., Ounissi-Benkalha, H., Tessier, M.-C., & Polychronakos, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206894200 · Cited by 293
Muller, A. F., Drexhage, H. A., & Berghout, A. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.5.0441 · Cited by 289
CTLA4 gene polymorphism and autoimmunity
Gough, S. C. L., Walker, L. S. K., & Sansom, D. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00249.x · Cited by 288
Thyrotropin receptor-associated diseases: from adenomata to Graves disease
Davies, T. F. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26031 · Cited by 262
The Genetics of Autoimmune Thyroid Disease
Vaidya, B., Kendall-Taylor, P., & Pearce, S. H. S. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020492 · Cited by 164
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
“Vogt-Koyanagi-Harada syndrome and Graves’ disease have been associated with inherited polymorphisms in the CTLA-4 gene.(60,64) It is thought that these inherited variants have defective CTLA-4 receptor function, leading to the activation and proliferation of T-cell lymphocytes.”
BackgroundDrug-Induced Graves Disease From CTLA-4 Receptor Suppression
Borodic, G., Hinkle, D. M., & Cia, Y. (2011) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0b013e3181ef72a1 · Cited by 120
Weetman, A. P. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03855.x · Cited by 77
Lazarus, J. H. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08015-4 · Cited by 59
Metadata
- Authors
- Yanagawa, T.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-01-01
- Volume
- 80
- Issue
- 1
- Pages
- 41-45
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2059442774
- Cited by
- 465
- References
- 0
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.